ATRS Insider Trading Activity and SEC Form 4 Filings
ATRS insider trading summary
No open-market insider purchases or sales of Antares Pharma, Inc. (ATRS) have been reported on SEC Form 4 in the past 12 months.
Latest ATRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 8, 2021 | Anton Gueth | Director | Sell | $429K (100,000 @ $4.29) |
| Mar 11, 2021 | Thomas J Garrity | Director | Sell | $214K (50,000 @ $4.28) |
| Feb 18, 2021 | Robert F Apple | President & CEO | Sell | $1.2M (232,156 @ $5.00) |
| Feb 18, 2021 | Robert F Apple | President & CEO | Sell | $89K (17,844 @ $5.01) |
| Feb 18, 2021 | Robert F Apple | President & CEO | Sell | $1.2M (241,960 @ $5.00) |
| Feb 18, 2021 | Leonard S Jacob | Director | Sell | $77K (15,321 @ $5.05) |
| Feb 18, 2021 | Peter J Graham | EVP General Counsel, Secretary | Sell | $196K (40,000 @ $4.91) |
| Feb 18, 2021 | Peter J Graham | EVP General Counsel, Secretary | Sell | $25K (5,000 @ $5.05) |
| Feb 17, 2021 | Robert F Apple | President & CEO | Sell | $26K (5,519 @ $4.75) |
| Feb 11, 2021 | Thomas J Garrity | Director | Sell | $231K (50,000 @ $4.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.